238 related articles for article (PubMed ID: 20300057)
1. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(10):299. PubMed ID: 20300057
[TBL] [Abstract][Full Text] [Related]
2. Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin.
Fagan RP; Neil KP; Sasich R; Luquez C; Asaad H; Maslanka S; Khalil W
Clin Infect Dis; 2011 Nov; 53(9):e125-8. PubMed ID: 21896700
[TBL] [Abstract][Full Text] [Related]
3. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin.
Yu PA; Lin NH; Mahon BE; Sobel J; Yu Y; Mody RK; Gu W; Clements J; Kim HJ; Rao AK
Clin Infect Dis; 2017 Dec; 66(suppl_1):S57-S64. PubMed ID: 29293928
[TBL] [Abstract][Full Text] [Related]
4. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.
Schussler E; Sobel J; Hsu J; Yu P; Meaney-Delman D; Grammer LC; Nowak-Wegrzyn A
Clin Infect Dis; 2017 Dec; 66(suppl_1):S65-S72. PubMed ID: 29293931
[TBL] [Abstract][Full Text] [Related]
5. Foodborne botulism treated with heptavalent botulism antitoxin.
Hill SE; Iqbal R; Cadiz CL; Le J
Ann Pharmacother; 2013 Feb; 47(2):e12. PubMed ID: 23362041
[TBL] [Abstract][Full Text] [Related]
6. Outbreak of foodborne botulism in Alexandria, Egypt: modulating indications for administration of heptavalent botulinum antitoxin.
Ghitani SA; Ghanem MA; Sultan EA; Atef M; Henaidy MF
Environ Sci Pollut Res Int; 2021 Nov; 28(43):61547-61553. PubMed ID: 34184216
[TBL] [Abstract][Full Text] [Related]
7. Type E botulism.
Horowitz BZ
Clin Toxicol (Phila); 2010 Nov; 48(9):880-95. PubMed ID: 21171846
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
9. Safety and Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.
Richardson JS; Parrera GS; Astacio H; Sahota H; Anderson DM; Hall C; Babinchak T
Clin Infect Dis; 2020 Apr; 70(9):1950-1957. PubMed ID: 31209461
[TBL] [Abstract][Full Text] [Related]
10. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
Dembek ZF; Smith LA; Rusnak JM
Disaster Med Public Health Prep; 2007 Nov; 1(2):122-34. PubMed ID: 18388640
[TBL] [Abstract][Full Text] [Related]
11. In brief: heptavalent botulism antitoxin.
Med Lett Drugs Ther; 2014 May; 56(1443):44. PubMed ID: 24869716
[No Abstract] [Full Text] [Related]
12. Botulism in the United States--1977. From the Center for Disease Control.
Gunn RA; Terranova WA
Rev Infect Dis; 1979; 1(4):722-5. PubMed ID: 233170
[No Abstract] [Full Text] [Related]
13. The role of a poison control center in identifying and limiting an outbreak of foodborne botulism.
Brown J; Sutter ME; Algren DA; Thomas JD; Ragone S; Schier JG; Geller RJ
Am J Prev Med; 2010 Jun; 38(6):675-8. PubMed ID: 20494246
[TBL] [Abstract][Full Text] [Related]
14. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Mar; 55(8):209-10. PubMed ID: 16511443
[TBL] [Abstract][Full Text] [Related]
15. Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.
Beliveau M; Anderson D; Barker D; Kodihalli S; Simard E; Hall C; Richardson JS
Clin Pharmacol Ther; 2022 Jul; 112(1):171-180. PubMed ID: 35467014
[TBL] [Abstract][Full Text] [Related]
16. Botulism and vaccines for its prevention.
Smith LA
Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283
[TBL] [Abstract][Full Text] [Related]
17. Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product.
Anderson DM; Kumar VR; Arper DL; Kruger E; Bilir SP; Richardson JS
PLoS One; 2019; 14(11):e0224700. PubMed ID: 31697731
[TBL] [Abstract][Full Text] [Related]
18. Establishment of vaccination clinics; user fees for investigational new drug (IND) influenza vaccine services and vaccines. Interim final rule and request for comments.
Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS)
Fed Regist; 2005 Jan; 70(15):3490-3. PubMed ID: 15669145
[TBL] [Abstract][Full Text] [Related]
19. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(42):1454-5. PubMed ID: 22031218
[TBL] [Abstract][Full Text] [Related]
20. Delayed Antitoxin Treatment of Two Adult Patients with Botulism after Cosmetic Injection of Botulinum Type A Toxin.
Fan KL; Wang YL; Chu G; Leung LP
J Emerg Med; 2016 Dec; 51(6):677-679. PubMed ID: 27687174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
